Clinical Trials
3 trialsNCT06613633 2026-04-29
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Fudan University
Completed
NCT06538038 2026-03-27
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
NCT07491211 2026-03-27
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
Fudan University
Active not recruiting